E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Non-sALCL PTCL and CD30 expression <10% |
LCTP non LAGCs et expression du CD30 <10% |
|
E.1.1.1 | Medical condition in easily understood language |
T-cell Lymphoma
|
Lymphome à cellules T |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10034624 |
E.1.2 | Term | Peripheral T-cell lymphoma unspecified NOS |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the objective response rate (ORR) per blinded independent central review (BICR) using the Revised Response Criteria for Malignant Lymphoma (Cheson 2007) |
Évaluer le taux de réponse objective (TRO) par un examen central indépendant en aveugle (ECIA) en utilisant les critères de réponse révisés pour le lymphome malin (Cheson 2007)
|
|
E.2.2 | Secondary objectives of the trial |
● To evaluate the complete response (CR) following completion of study treatment (Cheson 2007)
● To evaluate progression-free survival (PFS) (Cheson 2007)
● To evaluate overall survival (OS)
● To evaluate duration of response (DOR) (Cheson 2007)
● To evaluate ORR per BICR using modified Lugano criteria (Cheson 2014)
● To evaluate safety and tolerability |
● Évaluer la réponse complète (RC) après la fin du traitement à l’étude (Cheson 2007)
● Évaluer la survie sans progression (SSP) (Cheson 2007)
● Évaluer la survie globale (SG)
● Évaluer la durée de la réponse (DDR) (Cheson 2007)
● Évaluer le TRO d’après l’ECIA à l’aide des critères modifiés de Lugano (Cheson 2014)
● Évaluer la sécurité d’emploi et la tolérance
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1.Age 18 years or older.
2.Newly diagnosed PTCL, excluding systemic anaplastic large cell lymphoma (sALCL), per the Revised European-American Lymphoma World Health Organization (WHO) 2016 classification.
3.The following non-sALCL PTCL subtypes are eligible:
a.PTCL – not otherwise specified (PTCL-NOS)
b.Angioimmunoblastic T-cell lymphoma (AITL)
c.Adult T-cell leukemia/lymphoma (ATLL; acute and lymphoma types only, must be positive for human T cell leukemia virus 1)
d.Enteropathy-associated T-cell lymphoma (EATL)
e.Hepatosplenic T-cell lymphoma
f.Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITCL)
g.Indolent T-cell lymphoproliferative disorder (T-LPD) of the gastrointestinal (GI) tract
h.Follicular T-cell lymphoma
i.Nodal peripheral T-cell lymphoma with T-follicular helper (TFH) phenotype
4.CD30 expression <10% by local assessment
5.Fluorodeoxyglucose (FDG)-avid disease by PET and measurable disease of at least 1.5 cm by CT, as assessed by the site radiologist.
6.An Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2
Other protocol defined inclusion criteria may apply.
|
|
E.4 | Principal exclusion criteria |
1.Current diagnosis of any of the following:
a.sALCL
b.Primary cutaneous T-cell lymphoproliferative disorders and lymphomas
c.Mycosis fungoides (MF), including transformed MF
2.History of another primary invasive cancer, hematologic malignancy, or myelodysplastic syndrome that has not been in remission for at least 3 years. Exceptions are malignancies with a negligible risk of metastasis or death (e.g., 5-year OS ≥90%), such as carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer.
3.History of progressive multifocal leukoencephalopathy (PML).
4.Cerebral/meningeal disease related to the underlying malignancy.
5.Prior treatment with brentuximab vedotin.
Other protocol defined exclusion criteria may apply.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
ORR per BICR following the completion of study treatment using Revised Response Criteria for Malignant Lymphoma criteria (Cheson 2007) |
TRO par ECIA après la du traitement à l'étude, à l’aide des critères de réponse révisés pour le lymphome malin (Cheson 2007) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
6 months after last subject enrolled |
6 mois après le dernier patient inclus |
|
E.5.2 | Secondary end point(s) |
● Complete response rate per BICR (Cheson 2007)
● PFS per BICR (Cheson 2007)
● Overall survival (OS)
● Duration of response (DOR) per BICR
● ORR per BICR, using modified Lugano criteria (Cheson 2014)
● Type, incidence, severity, seriousness, and relatedness of adverse events
● Laboratory abnormalities |
● taux de réponse complète d'après l'ECIA (Cheson 2007)
● SSP d'après l'ECIA (Cheson 2007)
● Survie globale (SG)
● Durée de la réponse (DDR) d'après l'ECIA
● TRO d'après l'ECIA, à l'aide des critères modifiés de Lugano (Cheson 2014)
● Type, fréquence, gravité, sévérité et imputabilité des évènements indésirables
● anomalies dans les analyses de laboratoire |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
● 1 year after last subject enrolled
● 1 year after last subject enrolled
● 1 year after last subject enrolled
● 1 year after last subject enrolled
● 1 year after last subject enrolled
● 1 year after last subject enrolled
|
● 1 an après l'inclusion du dernier patient
● 1 an après l'inclusion du dernier patient
● 1 an après l'inclusion du dernier patient
● 1 an après l'inclusion du dernier patient
● 1 an après l'inclusion du dernier patient
● 1 an après l'inclusion du dernier patient |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 32 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Czech Republic |
France |
Italy |
Spain |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The study will be closed 2 years after enrollment of the last subject, or when no subjects remain in long-term follow-up, whichever occurs first. Additionally, the sponsor may terminate the study at any time.
The date the subject met criteria for study discontinuation and the reason for study discontinuation will be collected.
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | 30 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 1 |